Compounding pharmacy marketing: what 503A, 503B and FDA allow

A compounding pharmacy markets something unusual: a drug that FDA has not approved, made for a patient whose prescriber decided a commercially available product would not do. FDA describes compounding on its Human Drug Compounding page as a practice in which a pharmacist or physician “combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.” The same page states: “Compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed.” Every marketing decision follows from those two sentences.

This guide is for owners of compounding pharmacies, outsourcing facilities, and the practices and telehealth services that promote compounded drugs to patients. It covers the difference between section 503A and section 503B of the Federal Food, Drug, and Cosmetic Act, what happened to the old advertising limits, the claims FDA has warned about, and how Google Ads treats online pharmacies. Rewards, copay waivers and refill reminders are in our guide to independent pharmacy marketing, and compounded GLP-1 drugs are covered in weight loss clinic marketing, so this one stays on compounding itself. A clinic advertising a treatment it prescribes, including a compounded one, is covered in our guide to advertising a prescription treatment under FDA and FTC rules. IV drips and vitamin shot menus are covered in IV therapy clinic marketing. Compounded “lipodissolve” mixtures for fat removal are covered in our guide to fat-dissolving injection marketing.

503A and 503B are two different businesses

Federal law gives compounded drugs two separate paths around the requirements that apply to new drugs, and each path has its own conditions. A marketing plan has to start with which one the business uses.

Section 503A, 21 U.S.C. 353a, covers compounding by a licensed pharmacist in a state licensed pharmacy or a federal facility, or by a licensed physician. Its exemptions apply when the drug is “compounded for an identified individual patient based on the receipt of a valid prescription order” or a prescriber’s notation that a compounded product is necessary for that patient. The statute also allows compounding in limited quantities before a prescription arrives, but only based on a history of valid prescription orders generated within an established relationship with the patient or the prescriber. FDA’s questions and answers page says state boards of pharmacy generally have primary responsibility for day to day oversight of these pharmacies.

Section 503B, 21 U.S.C. 353b, covers outsourcing facilities. The statute defines an outsourcing facility as a facility at one geographic location or address that is engaged in the compounding of sterile drugs, has elected to register as an outsourcing facility and complies with all of the section’s requirements. It adds that an outsourcing facility “is not required to be a licensed pharmacy” and “may or may not obtain prescriptions for identified individual patients.” FDA’s questions and answers page says outsourcing facilities are primarily overseen by FDA, inspected on a risk-based schedule, and subject to current good manufacturing practice requirements, while drugs compounded under 503A are not.

The difference matters for who the audience is. A 503A pharmacy fills prescriptions for named patients. A 503B facility can supply health care settings, and the statute requires the label of a drug distributed without a prescription for an identified patient to carry the statement “Office Use Only”.

The advertising ban that is no longer in the statute

When Congress added section 503A in 1997, it included a subsection on advertising. As quoted in the amendment notes to 21 U.S.C. 353a, it allowed compounding only if the pharmacy, pharmacist or physician “does not advertise or promote the compounding of any particular drug, class of drug, or type of drug,” while allowing them to “advertise and promote the compounding service.” The original text also required the prescription to be “unsolicited”.

Public Law 113-54, the 2013 law that added section 503B, struck out that advertising subsection and the word “unsolicited”. The current text of 503A has no advertising section. Older articles and templates that still describe a federal ban on advertising particular compounded drugs are out of date.

That does not mean anything goes. A drug is misbranded under 21 U.S.C. 352(a)(1) if “its labeling is false or misleading in any particular”, and the 503A and 503B exemptions do not switch that provision off. Section 12 of the FTC Act, 15 U.S.C. 52, makes it unlawful to disseminate a false advertisement likely to induce the purchase of drugs or services, and section 5, 15 U.S.C. 45, prohibits deceptive acts or practices. FDA says on its telehealth page that promoting compounded drugs with false or misleading claims “violates federal law.” State pharmacy rules on advertising still apply on top of all of this.

Claims FDA has warned about

FDA’s page FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs says the agency has issued warning letters to telehealth companies over false or misleading claims about compounded drugs. The page reminds telehealth companies not to market compounded GLP-1 drugs to consumers with false or misleading claims, including:

• Branding on a website that falsely or misleadingly implies the telehealth company is the compounder.
• Describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug approved by FDA. FDA explains that generic drugs are approved by FDA prior to marketing, while a compounded drug is not.
• Claiming a compounded drug has been FDA-approved or otherwise evaluated for safety and effectiveness.
• Describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug.
• Claiming a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA states that it “does not approve or license any facility.”

The list is written for telehealth companies and GLP-1 drugs, but each item describes a claim about compounding in general. A pharmacy’s own website, a prescriber’s service page and a social post can make the same mistakes. Read your pages against it line by line.

The safe wording is plain. A compounded drug is a compounded drug. It is prepared by a named pharmacy or outsourcing facility, on a prescription where 503A applies, and it has not been reviewed by FDA for safety, effectiveness or quality. An outsourcing facility that is registered with FDA can say so, and patients or prescribers can check FDA’s published list of registered outsourcing facilities. “Registered” is not “approved” or “licensed”, and the words should not be swapped.

Copies of commercially available drugs

Both sections limit copying. Under 503A(b)(1)(D), a pharmacist or physician may not compound “regularly or in inordinate amounts” any drug products that are “essentially copies of a commercially available drug product.” Section 503A(b)(2) says a drug is not essentially a copy if there is a change, made for an identified individual patient, that produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the commercially available product.

Under 503B(a)(5), an outsourcing facility’s drug must not be “essentially a copy of one or more approved drugs.” The definition in 503B(d)(2) includes a drug that is identical or nearly identical to an approved drug, unless the approved drug appears on the drug shortage list in effect at the time of compounding, distribution and dispensing.

For marketing, this has a direct consequence. A campaign that sells a compounded drug as a cheaper version of a commercially available product describes the very thing the statute limits, and it also runs into the FDA warnings above about generic and same-as claims. Messages about what compounding is for, such as preparing a dosage form or removing an ingredient a patient cannot take, describe the patient-specific reason the law contemplates. Whether a compounded drug is right for a patient is the prescriber’s decision, and the marketing should say so.

Who is the compounder

FDA’s questions and answers page notes that patients who buy compounded drugs through online pharmacies and telehealth platforms “may not know the identity of the compounder that produced the drug,” including whether it meets appropriate quality standards and is appropriately licensed and regulated. The telehealth warning list treats branding that implies the wrong business is the compounder as a misleading claim.

If you are a practice or telehealth service that works with an outside pharmacy, name the pharmacy or outsourcing facility in the places a patient will look, and do not present its work as your own. If you are the pharmacy, make your name, license location and contact details easy to find. For an outsourcing facility, 503B(a)(10) requires the label to carry the statement “This is a compounded drug.” or a comparable statement, and the facility’s name, address and phone number. A website that says the same thing in plain words is consistent with the label.

FDA’s Understanding the Risks of Compounded Drugs page says that a compounded drug that does not meet appropriate quality standards, such as one that is contaminated or contains too much active ingredient, could cause serious injury or death. That is a reason to keep quality claims factual. Describe the standards you follow and the testing you actually do, and keep any document that backs a claim on file before the claim runs.

Health claims and evidence

The FTC’s Health Products Compliance Guidance applies to health claims about any product or service. It says health benefit claims need competent and reliable scientific evidence, and that an ad can make implied claims through images and context as well as through words. A compounded drug has no FDA review of effectiveness to lean on, so a claim that it treats, cures or works better than something else needs its own support. Compounded hormone pellets are a common example; our guide to hormone pellet therapy marketing covers what FDA and the 2020 National Academies report say about them.

Testimonials raise the same issues they do for any health business, plus HIPAA authorization questions when the patient’s story comes from your own records. Our guide to patient testimonials and before-and-after photos covers both.

Marketing to prescribers

Compounding pharmacies depend on prescribers, and that is where the federal anti-kickback statute comes in. Under 42 U.S.C. 1320a-7b(b), knowingly and willfully offering or paying remuneration to induce or reward referrals of items or services payable by a federal health care program is a crime, and receiving it is too. Payments to prescribers, marketers paid per prescription, and free items tied to orders all need review by counsel before they start. Our guide to patient and physician referrals explains the statute, its safe harbors and the Stark law.

Information for prescribers can still be useful and lawful: what dosage forms you prepare, how to send a prescription, turnaround as you actually measure it, how to reach a pharmacist, and the facts about 503A or 503B status. Leave out pre-filled order forms that steer a prescriber to a product line, and anything of value tied to the number of prescriptions.

If your pharmacy also runs point-of-care tests and, where your state allows, treats patients after a positive result, those services rest on a CLIA certificate and on state prescribing scope rather than on sections 503A and 503B. Our guide to pharmacist test-and-treat marketing covers how to describe them.

Google Ads for compounding pharmacies

Google’s Healthcare and medicines policy restricts the promotion of services related to the online prescribing, dispensing and sale of prescription drugs, and names online pharmacies among the businesses covered. Advertisers must apply to serve these ads, and location-specific rules apply. For the United States, the policy says Google allows online pharmacies accredited by one of the programs it lists, and that advertisers must also be certified with Google.

The same policy treats offering prescription drugs without a prescription, and targeting locations where you are not licensed, as egregious violations. It also restricts prescription drug terms in ads, landing pages and keywords. Campaign locations should match the places where the pharmacy holds a license. Ads about the pharmacy, its pharmacists and the service of compounding can leave out prescription drug terms, though a landing page that takes prescription orders online is still within the policy. Our healthcare ad policy basics guide covers the general rules.

Illustration: rewriting a compounding pharmacy’s home page

Illustration only, not a real business. A 503A compounding pharmacy’s home page opens with a large image of a brand-name product’s packaging and the line “The same medication, without the brand-name price. FDA-approved pharmacy.” A banner offers a discount to new patients who transfer their prescriptions.

Reviewed against the sources above, the headline makes a same-as claim and a price comparison against a commercially available product, which the FDA warning list and the 503A copies limit both speak to. “FDA-approved pharmacy” is a claim FDA says it never makes about any facility. The transfer discount needs the review described in our independent pharmacy guide before it runs for Medicare or Medicaid patients.

The rewritten page opens with what the pharmacy does: it prepares medications on a prescription when a prescriber decides a patient needs a form or strength that is not commercially available. It names the pharmacy, its license and its pharmacists, states that compounded drugs are not FDA approved, explains how a prescriber sends an order, and lists hours and contact details. The brand imagery and the transfer discount are gone.

Checklist

• Your website says which path you use, 503A or 503B, in plain words.
• No page calls a compounded drug FDA approved, generic, the same as, or clinically proven equal to an approved drug.
• No page calls a pharmacy or outsourcing facility FDA approved or FDA licensed; registered outsourcing facilities say “registered”.
• No brand-name product images, names or results used to sell a compounded drug.
• The compounder is named wherever a patient or prescriber orders.
• Every quality, turnaround and health claim has evidence on file before it runs.
• Prescriber programs and any payment to marketers reviewed under the anti-kickback statute by counsel.
• Google Ads campaigns target only states where you are licensed, with the required accreditation and Google certification in place.
• State board of pharmacy advertising rules checked for each state you serve.

How we help

We build websites, local search and Google Ads for independent health care businesses, with service pages and claims checked against the FDA warnings and statutes above before anything goes live. See our medical website design work. Our AI front desk is built with HIPAA in mind and can answer questions about hours, locations and how to send a prescription from a list you approve, and it passes clinical questions to a pharmacist. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We do not sell lead lists, do not pay for referrals and do not give legal advice; your counsel decides how these rules apply to you. See the full list in our healthcare marketing rules guide.

Sources

• 21 U.S.C. 353a: Pharmacy compounding (section 503A, including 2013 amendment notes)
• 21 U.S.C. 353b: Outsourcing facilities (section 503B)
• 21 U.S.C. 352: Misbranded drugs and devices (subsection (a))
• FDA: Human Drug Compounding (content current as of June 15, 2026)
• FDA: FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs (June 15, 2026)
• FDA: Compounding and the FDA: Questions and Answers (September 16, 2025)
• FDA: Understanding the Risks of Compounded Drugs (June 22, 2026)
• FDA: Registered Outsourcing Facilities
• 15 U.S.C. 52: Dissemination of false advertisements (FTC Act section 12)
• 15 U.S.C. 45: Section 5 of the FTC Act
• FTC: Health Products Compliance Guidance (December 2022)
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving federal health care programs (anti-kickback statute, subsection (b))
• Google Ads: Healthcare and medicines policy

More in Facilities, care services and pharmacy